Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 2 | 5 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 3 | 7 |
| 2011 | 3 | 2 | 5 |
| 2012 | 1 | 4 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 5 | 7 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 4 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.
-
Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells. 2022 Nov 27; 11(23).
-
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi. Melanoma Res. 2021 08 01; 31(4):319-327.
-
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem. 2021 Nov 15; 224:113672.
-
Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition. Elife. 2021 04 15; 10.
-
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020 10 13; 4(19):4640-4647.
-
Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. Mol Carcinog. 2020 08; 59(8):955-966.
-
Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nat Commun. 2020 05 11; 11(1):2354.
-
Activation of ß-Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids. J Clin Endocrinol Metab. 2020 04 01; 105(4).
-
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2. Bioorg Med Chem Lett. 2019 08 15; 29(16):2136-2140.